Biocon Biologics is a unique, fully integrated, global biosimilars company with world-class ‘lab to market’ capabilities across development, manufacturing, and marketing. It is present in over 120 countries, including over 80 Emerging Market countries, where it is providing sustainable solutions for a healthier world through its cost-effective, high-quality biosimilars.

Expanding Access to Lifesaving Therapies in LATAM

In the Latin America (LATAM) region, Biocon Biologics is making a significant impact on patients’ lives by expanding access to lifesaving treatments and life-improving therapies to treat diseases like diabetes, cancer, and autoimmune conditions through its 8 commercialized biosimilars.

Biocon Biologics has developed a differentiated portfolio of biosimilars spanning insulins, monoclonal antibodies and conjugated recombinant proteins by leveraging its deep experience in biotechnology. It addresses the needs of patients in the LATAM region through its state-of-the-art manufacturing infrastructure, which includes facilities for producing monoclonal antibodies in Bengaluru, India, and insulins in Johor, Malaysia.

Focused on Making a Meaningful Difference in Mexico

In Mexico, Biocon Biologics is focused on broadening access to biosimilars for treating cancer, diabetes and autoimmune disease for the benefit of patients and improving healthcare outcomes in Mexico. Biocon Biologics has three commercialized products in Mexico— Krabeva, a biosimilar to Avastin (Bevacizumab), used in the treatment of various cancers, including colorectal, lung, and kidney cancers, Basalog, a biosimilar to Lantus (Insulin Glargine), a long-acting insulin used to manage blood sugar levels in people with diabetes, and Insugen, a biosimilar to human insulin, used for the treatment of diabetes. 

Headquartered in Bengaluru, global biosimilars leader Biocon Biologics has a longstanding presence in the industry, having invested over $1 billion in R&D and global-scale manufacturing over the past two decades. The integration of the global biosimilars business acquired from its long-term partner has further strengthened Biocon Biologics’ commercial presence in Mexico. As a trusted and reliable company, Biocon Biologics is poised to grow and consolidate its leadership in biosimilars in Mexico, making a meaningful impact on patients’ lives.

In Mexico, Bevacizumab is commercialized by our partner Synthon Mexico, and Insulin Glargine and Rh-Insulin are commercialized by our partner Laboratios PISA.